Skip to main content
Log in

Road to nowhere with phospholipase enzyme inhibitors

  • Newsletter Article
  • Published:
Inpharma Weekly

&

Researchers are making little progress in developing effective phospholipase enzyme inhibitors with potential use as anti-inflammatory or antineoplastic agents. Some companies are giving up the search, whereas others are looking at less direct ways of inhibiting the enzymes. An alternative approach may be to find earlier targets in the pathway leading to phospholipase activation. In this respect, some encouraging results have been achieved by inhibiting tyrosine kinases. However, further research is needed, as discussed at The Society for Medicines Research meeting entitled, ‘Choline Lipids and Their Role in Cellular Signalling’ [ London, UK; March 1995 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mundell, I. Road to nowhere with phospholipase enzyme inhibitors. Inpharma Wkly. 982, 9–10 (1995). https://doi.org/10.2165/00128413-199509820-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199509820-00014

Keywords

Navigation